ATE483972T1 - Reagenzien und verfahren für krebsprognose und pathologische einstufung - Google Patents

Reagenzien und verfahren für krebsprognose und pathologische einstufung

Info

Publication number
ATE483972T1
ATE483972T1 AT07757161T AT07757161T ATE483972T1 AT E483972 T1 ATE483972 T1 AT E483972T1 AT 07757161 T AT07757161 T AT 07757161T AT 07757161 T AT07757161 T AT 07757161T AT E483972 T1 ATE483972 T1 AT E483972T1
Authority
AT
Austria
Prior art keywords
reagents
methods
cancer prognosis
pathological grading
grading
Prior art date
Application number
AT07757161T
Other languages
English (en)
Inventor
Gary Pestano
Linda Samadzadeh
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of ATE483972T1 publication Critical patent/ATE483972T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07757161T 2006-02-16 2007-02-16 Reagenzien und verfahren für krebsprognose und pathologische einstufung ATE483972T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77456306P 2006-02-16 2006-02-16
PCT/US2007/062362 WO2007095644A2 (en) 2006-02-16 2007-02-16 Reagents and methods for cancer prognosis and pathological staging

Publications (1)

Publication Number Publication Date
ATE483972T1 true ATE483972T1 (de) 2010-10-15

Family

ID=38335516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07757161T ATE483972T1 (de) 2006-02-16 2007-02-16 Reagenzien und verfahren für krebsprognose und pathologische einstufung

Country Status (10)

Country Link
US (2) US20070207489A1 (de)
EP (2) EP1984735B1 (de)
JP (1) JP5143026B2 (de)
CN (2) CN104749378A (de)
AT (1) ATE483972T1 (de)
AU (1) AU2007214427B2 (de)
CA (1) CA2642542C (de)
DE (1) DE602007009645D1 (de)
ES (1) ES2354181T3 (de)
WO (1) WO2007095644A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009537154A (ja) 2006-05-18 2009-10-29 モレキュラー プロファイリング インスティテュート， インコーポレイテッド 疾患状態に対する個別化された医学的介入を決定するためのシステムおよび方法
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US9697582B2 (en) 2006-11-16 2017-07-04 Visiopharm A/S Methods for obtaining and analyzing images
WO2008143849A2 (en) 2007-05-14 2008-11-27 Historx, Inc. Compartment segregation by pixel characterization using image data clustering
WO2008156669A1 (en) 2007-06-15 2008-12-24 Historx, Inc. Method and system for standardizing microscope instruments
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009029810A1 (en) 2007-08-31 2009-03-05 Historx, Inc. Automatic exposure time selection for imaging tissue
EP2327040B1 (de) 2008-08-15 2013-12-18 Visiopharm A/s Verfahren und system zum bestimmen eines ziels in einer biologischen probe durch bildanalyse
EP3216874A1 (de) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Verfahren zum stratifizieren und annotieren der behandlungsoptionen eines krebsmedikaments
EP2335221B8 (de) 2008-09-16 2016-05-25 Novartis AG Reproduzierbare quantifizierung einer biomarkerexpression
CA2743211A1 (en) 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems of using exosomes for determining phenotypes
WO2010066252A1 (en) * 2008-12-09 2010-06-17 Dako Denmark A/S Method for evaluating pre-treatment
CA2749601C (en) 2009-01-14 2020-07-21 Stephen M. Hewitt Ratio based biomarkers and methods of use thereof
EP2542696B1 (de) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Theranostik-biomarker
BR112012025593A2 (pt) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
RU2012148816A (ru) * 2010-05-07 2014-06-20 Ф. Хоффманн-Ля Рош Аг Метод диагностики для определения клеток ex vivo
CN101876659B (zh) * 2010-06-29 2013-02-13 同济大学 用于检测肿瘤的量子点试剂盒
EP3572528A1 (de) 2010-09-24 2019-11-27 The Board of Trustees of the Leland Stanford Junior University Direkte erfassung, amplifikation und sequenzierung einer ziel-dna unter verwendung immobilisierter primer
US9410207B2 (en) * 2011-12-30 2016-08-09 Abbott Molecular Inc. Method and compositions for detecting epidermal growth factor receptor variant forms in cancer cells
WO2015028974A2 (en) * 2013-08-30 2015-03-05 Nestec S.A. Polyp recurrence
EP4040156A1 (de) * 2014-01-28 2022-08-10 Quest Diagnostics Investments Incorporated Verfahren zum nachweis eines adenom-adenokarzinom-übergangs bei krebs
CN103882139B (zh) * 2014-04-04 2015-06-03 上海赛安生物医药科技有限公司 一种用于化疗方案选择的多重基因检测试剂盒
EP3249401B1 (de) 2015-01-22 2019-12-25 Konica Minolta, Inc. Quantifizierungsverfahren für biologische substanz, pathologisches diagnoseunterstützungssystem und programm
US10517823B1 (en) * 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
CN107688092B (zh) * 2017-08-18 2020-05-19 国家纳米科学中心 一种用于癌症患者预后评估的方法
CN111819443A (zh) 2018-02-28 2020-10-23 日东纺绩株式会社 从固定化细胞或ffpe组织切片脱离增强抗原性的细胞核的方法以及用于该方法的抗原活化剂及试剂盒

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US6872817B1 (en) 1986-01-16 2005-03-29 The Regents Of The Univ. Of California Method of staining target interphase chromosomal DNA
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6649359B2 (en) * 2000-06-01 2003-11-18 The Brigham & Women's Hospital, Inc. Diagnosis of endometrial precancers
EP1360496A4 (de) * 2001-02-16 2005-03-09 Immunivest Corp Verfahren und reagenzien zur schnellen und effizienten isolierung zirkulierender krebszellen
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
AU2003251597A1 (en) * 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
US7576074B2 (en) * 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
EP1567860A4 (de) * 2002-11-05 2006-05-10 Univ California Verfahren und materialien zur untersuchung von mit glioblastomprogression assoziierten wegen
EP1636380A2 (de) * 2003-05-30 2006-03-22 Genomic Health, Inc. Genexpressionsmarker zur reaktion auf egfr-inhibitor-arzneistoffe
DE10345021A1 (de) * 2003-09-23 2005-05-04 Univ Potsdam Verfahren zur nichtinvasiven Früherkennung von Dickdarmkrebs und/oder Darmkrebsvorläuferzellen
WO2005118878A2 (en) * 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
WO2005118876A2 (en) * 2004-06-04 2005-12-15 Genentech, Inc. Egfr mutations
JP2008515915A (ja) * 2004-10-07 2008-05-15 エモリー ユニバーシティー 多機能性ナノ粒子結合体およびそれらの使用
EP2473495A1 (de) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmazeutische verbindungen

Also Published As

Publication number Publication date
AU2007214427A1 (en) 2007-08-23
US20070207489A1 (en) 2007-09-06
CA2642542A1 (en) 2007-08-23
WO2007095644A2 (en) 2007-08-23
EP1984735A2 (de) 2008-10-29
JP2009527740A (ja) 2009-07-30
US20100184099A1 (en) 2010-07-22
ES2354181T3 (es) 2011-03-10
CN104749378A (zh) 2015-07-01
DE602007009645D1 (de) 2010-11-18
CA2642542C (en) 2012-09-25
AU2007214427B2 (en) 2011-11-10
WO2007095644A3 (en) 2007-12-27
EP1984735B1 (de) 2010-10-06
EP2290361A1 (de) 2011-03-02
CN101384901A (zh) 2009-03-11
JP5143026B2 (ja) 2013-02-13

Similar Documents

Publication Publication Date Title
ATE483972T1 (de) Reagenzien und verfahren für krebsprognose und pathologische einstufung
DE602006002809D1 (de) Verfahren zur erkennung eines ovarialkarzinoms
EP2047262A4 (de) Verfahren zur krebsprognose auf der basis subzellulärer lokalisierung von biomarkern
EP1969363A4 (de) Verfahren und markerkombinationen zum screening auf eine veranlagung zu lungenkrebs
IN2013CN01129A (de)
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
WO2008154098A3 (en) Reagents and methods for mirna expression analysis and identification of cancer biomarkers
EP1991701A4 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von krebs
DE112006001755A5 (de) EU/TB-Chelat-basiertes fluoreszenzspektroskopisches Verfahren zum Nachweis von Analyten
DK2211180T3 (da) Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer
ATE410524T1 (de) Verfahren und nukleinsäuren für die analyse von zellulären proliferationsstörungen
WO2006052823A3 (en) Biomarkers for prostate cancer metastasis
EP2177614A3 (de) Zusammensetzung und Verfahren zur Diagnose von Speiseröhrenkrebs sowie der Metastasierung von Speiseröhrenkrebs
WO2013057581A8 (en) Composite biomarker for non-invasive screening, diagnosis and prognosis of colorectal cancer
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
EA201370063A1 (ru) Фосфолипидом рака
ATE557276T1 (de) Spezifisches verfahren zum krebsnachweis
DE60323685D1 (de) Tumor marker für urothelialen krebs
WO2007082073A8 (en) Biomarkers for oral tongue cancer metastasis and extracapsular spread (ecs)
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
EP1774043A4 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von krebs
ATE433158T1 (de) System und verfahren zur erkennung der breite eines datenbusses
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
WO2008104985A3 (en) Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers
DE112007003222A5 (de) Prognostische Marker für die Klassifizierung von kolorektalen Karzinomen basierend auf Expressionsprofilen von biologischen Proben

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties